Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 6 consecutive quarters of double digit growth.
Click here to learn more ›

March 2013

Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides

Press Releases / By

CRANBURY, N.J., March 19, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial …

Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides Read More »

Palatin Technologies To Present At The 25th Annual ROTH Conference

Press Releases / By

CRANBURY, N.J., March 15, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 25th Annual ROTH Conference on Monday, March 18, 2013, at 1:00 p.m. Pacific Time.  The conference will be held at the Ritz Carlton Laguna Niguel in Dana Point, CA. Carl Spana, Ph.D., President and Chief …

Palatin Technologies To Present At The 25th Annual ROTH Conference Read More »

Scroll to Top